¿Es cierto que las estatinas y los IECAS deben administrarse en diferentes momentos del día, es decir, estatinas por la noche y los IECAS por la mañana? ¿Cómo afecta eso a la toma de Trinomia?

Referencias

1. Marzal D, Rodríguez Padial L, Arnáiz JA, Castro A, Cosín J, Lekuona I, et al. Use of the cardiovascular polypill 40 mg in secondary cardiovascular prevention. Clin Investig Arterioscler. 2018;30(5):240-247.
2. Piepoli F, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016 Aug 1;37(29):2315-2381.
3. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: supplementary data. European Heart Journal. 2019;00:1-18.
4. Ibánez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2017 Dec;70(12):1082.
5. González-Juanatey JR, Mostaza JM, Lobos JM, Abarca B, Llisterri JL. Un paso más allá en la prevención secundaria del riesgo cardiovascular. Documento de consenso del uso clínico del policomprimido. Rev Esp Cardiol 2016;69:547-50.
6. Castellano JM, Verdejo J, Ocampo S, Ríos MM, Gómez-Álvarez E, Borrayo G, et al., Clinical Effectiveness of the Cardiovascular Polipíldora in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study. Arch Med Res. 2019; 50:31e40.
7. González-Juanatey JR, Tamargo J, Torres F, Weisser B, Oudovenko N. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents? Rev Esp Cardiol (Engl Ed). 2020. pii:S1885-5857(19)30415-3.
8. Cosin-Sales J, Murcia-Zaragoza JM, Pereyra-Rico HO, de la Guia-Galipienso F, Hermans K, Rubio G. An observational, international, cohort study to evaluate the satisfaction and preferences of patients in preventive treatment of secondary cardiovascular events with a cardiovascular polypill. Value in Health; 2019; 22 (suppl 3): S566-S567.
9. Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L. A polipíldora strategy to improve adherence: results from the FOCUS project. .J Am Coll Cardiol. 2014 18-25;64:2071-82.
10. CIMA. Ficha técnica Trinomia; 2021 [último acceso marzo 2021]. Disponible en: https://cima.aemps.es/cima/dochtml/ft/81773/FT_81773.html
11. CIMA. Ficha técnica Acovil (ramipril). Sanofi-Aventis, S.A.; 2021 [último acceso marzo 2021]. Disponible en:
    https://www.aemps.gob.es/cima/pdfs/es/ft/59564/FichaTecnica_59564.html.pdf
    https://www.aemps.gob.es/cima/dochtml/ft/59564/FichaTecnica_59564.html
12. CIMA. Ficha técnica Cardyl (atorvastatina). Pfizer, S.L.; 2021 [último acceso marzo 2021]. Disponible en: https://www.aemps.gob.es/cima/pdfs/es/ft/61716/FichaTecnica_61716.html.pdf
13. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz N, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45.
14. Masjuan J, Gállego J, Aguilera JM, Arenillas JF, Castellanos M, Díaz F, et al. Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. Neurologia. 2021 Jan-Feb;36(1):1-8.
15. Guía Salud. Clasificación etiológica del ictus; 2009 [último acceso abril del 2021]. Disponible en: http://www.guiasalud.es/egpc/i....
16. Park JH, Ovbiagele B. Optimal combination secondary prevention drug treatment and stroke outcomes. Neurology. 2015;84(1):50-6.
17. Ros-Castelló V, Natera-Villalba E, Gómez-López A, Sánchez-Sánchez A, Chico-García JL, García-Madrona S, et al. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients. Cerebrovasc Dis Extra. 2020 Nov 11;10(3):166-173.
18. Mezzano SA, Aros AE. Enfermedad renal crónica: clasificación, mecanismos de progresión y estrategias de renoprotección. Rev Med Chile. 2005; 133: 338-348.
19. MedlinePlus. Enfermedad renal crónica [último acceso febrero 2021]. Disponible en "https://medlineplus.gov/spanis...
20. Eknoyan G, Lameire N, Eckardt K-U, Kasiske BL, Wheeler DC, Abboud OI, et al., Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International Supplements.2012; 2: 337; doi:10.1038/kisup.2012.46
21. Eknoyan G, Lameire N, Eckardt K-U, Kasiske BL, Wheeler DC, Abboud OI, et al., KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Chapter 2: Pharmacological Cholesterol lowering treatment in adults. Kidney International Supplements. 2013; 3:262; doi:10.1038/ kisup.2013.30
22. Eknoyan G, Lameire N, Eckardt K-U, Kasiske BL, Wheeler DC, Abboud OI, et al. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney International Supplements. 2013;3:1; doi:10.1038/ kisup.2012.73
23. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012; 55:566–578.